Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 173

1.

Immune-Related Adverse Events Requiring Hospitalization: Spectrum of Toxicity, Treatment, and Outcomes.

Balaji A, Zhang J, Wills B, Marrone KA, Elmariah H, Yarchoan M, Zimmerman JW, Hajjir K, Venkatraman D, Armstrong DK, Laheru DA, Mehra R, Ho WJ, Reuss JE, Heng J, Vellanki P, Donehower RC, Holdhoff M, Naidoo J.

J Oncol Pract. 2019 Sep;15(9):e825-e834. doi: 10.1200/JOP.18.00703. Epub 2019 Aug 6.

PMID:
31386608
2.

Olaparib in combination with irinotecan, cisplatin, and mitomycin C in patients with advanced pancreatic cancer.

Yarchoan M, Myzak MC, Johnson BA 3rd, De Jesus-Acosta A, Le DT, Jaffee EM, Azad NS, Donehower RC, Zheng L, Oberstein PE, Fine RL, Laheru DA, Goggins M.

Oncotarget. 2017 Jul 4;8(27):44073-44081. doi: 10.18632/oncotarget.17237.

3.

Effects of the leucovorin shortage: Pilot study investigating cost, efficacy, and toxicity comparison of low fixed-dose versus body surface area-adjusted leucovorin dosing in patients with resectable colon or metastatic colorectal cancer.

Shank BR, Seung AH, Kinsman K, Newman MJ, Donehower RC, Burton B.

J Oncol Pharm Pract. 2017 Apr;23(3):163-172. doi: 10.1177/1078155215624262. Epub 2016 Jul 8.

PMID:
26763004
4.

Phase 1 Study of ABT-751 in Combination With CAPIRI (Capecitabine and Irinotecan) and Bevacizumab in Patients With Advanced Colorectal Cancer.

Rudek MA, Dasari A, Laheru D, He P, Jin R, Walker R, Taylor GE, Jimeno A, Donehower RC, Hidalgo M, Messersmith WA, Purcell WT.

J Clin Pharmacol. 2016 Aug;56(8):966-73. doi: 10.1002/jcph.681. Epub 2016 Feb 2.

5.

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.

Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, Biedrzycki B, Donehower RC, Zaheer A, Fisher GA, Crocenzi TS, Lee JJ, Duffy SM, Goldberg RM, de la Chapelle A, Koshiji M, Bhaijee F, Huebner T, Hruban RH, Wood LD, Cuka N, Pardoll DM, Papadopoulos N, Kinzler KW, Zhou S, Cornish TC, Taube JM, Anders RA, Eshleman JR, Vogelstein B, Diaz LA Jr.

N Engl J Med. 2015 Jun 25;372(26):2509-20. doi: 10.1056/NEJMoa1500596. Epub 2015 May 30.

6.

Exposure-response analysis of rilotumumab in gastric cancer: the role of tumour MET expression.

Zhu M, Tang R, Doshi S, Oliner KS, Dubey S, Jiang Y, Donehower RC, Iveson T, Loh EY, Zhang Y.

Br J Cancer. 2015 Feb 3;112(3):429-37. doi: 10.1038/bjc.2014.649. Epub 2015 Jan 13.

7.

A phase I trial of vertical inhibition of IGF signalling using cixutumumab, an anti-IGF-1R antibody, and selumetinib, an MEK 1/2 inhibitor, in advanced solid tumours.

Wilky BA, Rudek MA, Ahmed S, Laheru DA, Cosgrove D, Donehower RC, Nelkin B, Ball D, Doyle LA, Chen H, Ye X, Bigley G, Womack C, Azad NS.

Br J Cancer. 2015 Jan 6;112(1):24-31. doi: 10.1038/bjc.2014.515. Epub 2014 Sep 30.

8.

Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study.

Iveson T, Donehower RC, Davidenko I, Tjulandin S, Deptala A, Harrison M, Nirni S, Lakshmaiah K, Thomas A, Jiang Y, Zhu M, Tang R, Anderson A, Dubey S, Oliner KS, Loh E.

Lancet Oncol. 2014 Aug;15(9):1007-18. doi: 10.1016/S1470-2045(14)70023-3. Epub 2014 Jun 22.

PMID:
24965569
9.

Familial GI Stromal Tumor With Loss of Heterozygosity and Amplification of Mutant KIT.

Forde PM, Cochran RL, Boikos SA, Zabransky DJ, Beaver JA, Meyer CF, Thornton KA, Montgomery EA, Lidor AO, Donehower RC, Park BH.

J Clin Oncol. 2016 Jan 20;34(3):e13-6. doi: 10.1200/JCO.2013.51.6633. Epub 2014 May 27. No abstract available.

PMID:
24868028
10.

Interventions for preventing neuropathy caused by cisplatin and related compounds.

Albers JW, Chaudhry V, Cavaletti G, Donehower RC.

Cochrane Database Syst Rev. 2014 Mar 31;(3):CD005228. doi: 10.1002/14651858.CD005228.pub4. Review.

PMID:
24687190
11.

Incidence and prognostic impact of KRAS and BRAF mutation in patients undergoing liver surgery for colorectal metastases.

Karagkounis G, Torbenson MS, Daniel HD, Azad NS, Diaz LA Jr, Donehower RC, Hirose K, Ahuja N, Pawlik TM, Choti MA.

Cancer. 2013 Dec 1;119(23):4137-44. doi: 10.1002/cncr.28347. Epub 2013 Sep 19.

12.

Correlation of Smad4 status with outcomes in patients receiving erlotinib combined with adjuvant chemoradiation and chemotherapy after resection for pancreatic adenocarcinoma.

Herman JM, Fan KY, Wild AT, Wood LD, Blackford AL, Donehower RC, Hidalgo M, Schulick RD, Edil BH, Choti MA, Hruban RH, Pawlik TM, Cameron JL, Laheru DA, Iacobuzio-Donahue CA, Wolfgang CL.

Int J Radiat Oncol Biol Phys. 2013 Nov 1;87(3):458-9. doi: 10.1016/j.ijrobp.2013.06.2039. No abstract available.

13.

Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer.

Le DT, Lutz E, Uram JN, Sugar EA, Onners B, Solt S, Zheng L, Diaz LA Jr, Donehower RC, Jaffee EM, Laheru DA.

J Immunother. 2013 Sep;36(7):382-9. doi: 10.1097/CJI.0b013e31829fb7a2.

14.

Phase 2 study of erlotinib combined with adjuvant chemoradiation and chemotherapy in patients with resectable pancreatic cancer.

Herman JM, Fan KY, Wild AT, Hacker-Prietz A, Wood LD, Blackford AL, Ellsworth S, Zheng L, Le DT, De Jesus-Acosta A, Hidalgo M, Donehower RC, Schulick RD, Edil BH, Choti MA, Hruban RH, Pawlik TM, Cameron JL, Laheru DA, Wolfgang CL.

Int J Radiat Oncol Biol Phys. 2013 Jul 15;86(4):678-85. doi: 10.1016/j.ijrobp.2013.03.032.

15.

Randomized phase III multi-institutional study of TNFerade biologic with fluorouracil and radiotherapy for locally advanced pancreatic cancer: final results.

Herman JM, Wild AT, Wang H, Tran PT, Chang KJ, Taylor GE, Donehower RC, Pawlik TM, Ziegler MA, Cai H, Savage DT, Canto MI, Klapman J, Reid T, Shah RJ, Hoffe SE, Rosemurgy A, Wolfgang CL, Laheru DA.

J Clin Oncol. 2013 Mar 1;31(7):886-94. doi: 10.1200/JCO.2012.44.7516. Epub 2013 Jan 22.

16.

Phase I pharmacokinetic and pharmacodynamic study of cetuximab, irinotecan and sorafenib in advanced colorectal cancer.

Azad N, Dasari A, Arcaroli J, Taylor GE, Laheru DA, Carducci MA, McManus M, Quackenbush K, Wright JJ, Hidalgo M, Diaz LA Jr, Donehower RC, Zhao M, Rudek MA, Messersmith WA.

Invest New Drugs. 2013 Apr;31(2):345-54. doi: 10.1007/s10637-012-9820-z. Epub 2012 May 22.

17.

Phase I dose-escalation study to examine the safety and tolerability of LY2603618, a checkpoint 1 kinase inhibitor, administered 1 day after pemetrexed 500 mg/m(2) every 21 days in patients with cancer.

Weiss GJ, Donehower RC, Iyengar T, Ramanathan RK, Lewandowski K, Westin E, Hurt K, Hynes SM, Anthony SP, McKane S.

Invest New Drugs. 2013 Feb;31(1):136-44. doi: 10.1007/s10637-012-9815-9. Epub 2012 Apr 11.

18.

A multicenter analysis of GTX chemotherapy in patients with locally advanced and metastatic pancreatic adenocarcinoma.

De Jesus-Acosta A, Oliver GR, Blackford A, Kinsman K, Flores EI, Wilfong LS, Zheng L, Donehower RC, Cosgrove D, Laheru D, Le DT, Chung K, Diaz LA Jr.

Cancer Chemother Pharmacol. 2012 Feb;69(2):415-24. doi: 10.1007/s00280-011-1704-y. Epub 2011 Jul 29.

19.

Interventions for preventing neuropathy caused by cisplatin and related compounds.

Albers JW, Chaudhry V, Cavaletti G, Donehower RC.

Cochrane Database Syst Rev. 2011 Feb 16;(2):CD005228. doi: 10.1002/14651858.CD005228.pub3. Review. Update in: Cochrane Database Syst Rev. 2014;3:CD005228.

20.

Phase I trial of oxaliplatin, infusional 5-fluorouracil, and leucovorin (FOLFOX4) with erlotinib and bevacizumab in colorectal cancer.

Messersmith WA, Jimeno A, Jacene H, Zhao M, Kulesza P, Laheru DA, Kahn Y, Spira A, Dancey J, Iacobuzio-Donahue C, Donehower RC, Carducci M, Rudek MA, Hidalgo M.

Clin Colorectal Cancer. 2010 Dec;9(5):297-304. doi: 10.3816/CCC.2010.n.043.

21.

A tolerability and pharmacokinetic study of adjuvant erlotinib and capecitabine with concurrent radiation in resected pancreatic cancer.

Ma WW, Herman JM, Jimeno A, Laheru D, Messersmith WA, Wolfgang CL, Cameron JL, Pawlik TM, Donehower RC, Rudek MA, Hidalgo M.

Transl Oncol. 2010 Dec 1;3(6):373-9.

22.

Make quality cancer survivorship care possible in the era of workforce shortage.

Lin J, Donehower RC.

J Oncol Pract. 2010 Jan;6(1):52-3. doi: 10.1200/JOP.091056. No abstract available.

23.

Thymidylate synthase (TYMS) enhancer region genotype-directed phase II trial of oral capecitabine for 2nd line treatment of advanced pancreatic cancer.

Weekes CD, Nallapareddy S, Rudek MA, Norris-Kirby A, Laheru D, Jimeno A, Donehower RC, Murphy KM, Hidalgo M, Baker SD, Messersmith WA.

Invest New Drugs. 2011 Oct;29(5):1057-65. doi: 10.1007/s10637-010-9413-7. Epub 2010 Mar 23.

24.

A phase I dose-finding study of 5-azacytidine in combination with sodium phenylbutyrate in patients with refractory solid tumors.

Lin J, Gilbert J, Rudek MA, Zwiebel JA, Gore S, Jiemjit A, Zhao M, Baker SD, Ambinder RF, Herman JG, Donehower RC, Carducci MA.

Clin Cancer Res. 2009 Oct 1;15(19):6241-9. doi: 10.1158/1078-0432.CCR-09-0567. Epub 2009 Sep 29.

25.

Evaluation of the novel mitotic modulator ON 01910.Na in pancreatic cancer and preclinical development of an ex vivo predictive assay.

Jimeno A, Chan A, Cusatis G, Zhang X, Wheelhouse J, Solomon A, Chan F, Zhao M, Cosenza SC, Ramana Reddy MV, Rudek MA, Kulesza P, Donehower RC, Reddy EP, Hidalgo M.

Oncogene. 2009 Jan 29;28(4):610-8. doi: 10.1038/onc.2008.424. Epub 2008 Nov 24.

26.

Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors.

Jimeno A, Li J, Messersmith WA, Laheru D, Rudek MA, Maniar M, Hidalgo M, Baker SD, Donehower RC.

J Clin Oncol. 2008 Dec 1;26(34):5504-10. doi: 10.1200/JCO.2008.17.9788. Epub 2008 Oct 27.

27.

Pharmacodynamic-guided modified continuous reassessment method-based, dose-finding study of rapamycin in adult patients with solid tumors.

Jimeno A, Rudek MA, Kulesza P, Ma WW, Wheelhouse J, Howard A, Khan Y, Zhao M, Jacene H, Messersmith WA, Laheru D, Donehower RC, Garrett-Mayer E, Baker SD, Hidalgo M.

J Clin Oncol. 2008 Sep 1;26(25):4172-9. doi: 10.1200/JCO.2008.16.2347.

28.

Phase I trial of weekly trabectedin (ET-743) and gemcitabine in patients with advanced solid tumors.

Messersmith WA, Jimeno A, Ettinger D, Laheru D, Brahmer J, Lansey D, Khan Y, Donehower RC, Elsayed Y, Zannikos P, Hidalgo M.

Cancer Chemother Pharmacol. 2008 Dec;63(1):181-8. doi: 10.1007/s00280-008-0733-7. Epub 2008 Apr 1.

29.

Phase I study of troxacitabine administered by continuous infusion in subjects with advanced solid malignancies.

Jimeno A, Messersmith WA, Lee CK, Ma WW, Laheru D, Donehower RC, Baker SD, Hidalgo M.

Ann Oncol. 2008 Feb;19(2):374-9. doi: 10.1093/annonc/mdm572.

30.

Validation and implementation of a liquid chromatography/tandem mass spectrometry assay to quantitate ON 01910.Na, a mitotic progression modulator, in human plasma.

Li J, Zhao M, Jimeno A, He P, Ramana Reddy MV, Hidalgo M, Donehower RC, Rudek MA.

J Chromatogr B Analyt Technol Biomed Life Sci. 2007 Sep 1;856(1-2):198-204. Epub 2007 Jun 7.

31.

Phase I and pharmacokinetic study of UCN-01 in combination with irinotecan in patients with solid tumors.

Jimeno A, Rudek MA, Purcell T, Laheru DA, Messersmith WA, Dancey J, Carducci MA, Baker SD, Hidalgo M, Donehower RC.

Cancer Chemother Pharmacol. 2008 Mar;61(3):423-33. Epub 2007 Apr 12.

32.

Adjuvant concurrent chemoradiation for node-positive adenocarcinoma of the duodenum.

Swartz MJ, Hughes MA, Frassica DA, Herman J, Yeo CJ, Riall TS, Lillemoe KD, Cameron JL, Donehower RC, Laheru DA, Hruban RH, Abrams RA.

Arch Surg. 2007 Mar;142(3):285-8.

PMID:
17372054
33.

Adjuvant concurrent chemoradiation for adenocarcinoma of the distal common bile duct.

Hughes MA, Frassica DA, Yeo CJ, Riall TS, Lillemoe KD, Cameron JL, Donehower RC, Laheru DA, Hruban RH, Abrams RA.

Int J Radiat Oncol Biol Phys. 2007 May 1;68(1):178-82. Epub 2007 Feb 2.

PMID:
17276614
34.

Phase I study of continuous weekly dosing of dimethylamino benzoylphenylurea (BPU) in patients with solid tumours.

Messersmith WA, Rudek MA, Baker SD, Zhao M, Collins C, Colevas AD, Donehower RC, Carducci MA, Wolff AC.

Eur J Cancer. 2007 Jan;43(1):78-86. Epub 2006 Nov 3.

35.

Phase II study of erlotinib in patients with advanced biliary cancer.

Philip PA, Mahoney MR, Allmer C, Thomas J, Pitot HC, Kim G, Donehower RC, Fitch T, Picus J, Erlichman C.

J Clin Oncol. 2006 Jul 1;24(19):3069-74.

PMID:
16809731
36.

Phase I trial of bortezomib in combination with docetaxel in patients with advanced solid tumors.

Messersmith WA, Baker SD, Lassiter L, Sullivan RA, Dinh K, Almuete VI, Wright JJ, Donehower RC, Carducci MA, Armstrong DK.

Clin Cancer Res. 2006 Feb 15;12(4):1270-5.

37.

Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer.

Philip PA, Mahoney MR, Allmer C, Thomas J, Pitot HC, Kim G, Donehower RC, Fitch T, Picus J, Erlichman C.

J Clin Oncol. 2005 Sep 20;23(27):6657-63.

PMID:
16170173
38.

A phase I and pharmacokinetic study of short infusions of UCN-01 in patients with refractory solid tumors.

Dees EC, Baker SD, O'Reilly S, Rudek MA, Davidson SB, Aylesworth C, Elza-Brown K, Carducci MA, Donehower RC.

Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):664-71. No abstract available.

39.

Phase I trial of irinotecan, infusional 5-fluorouracil, and leucovorin (FOLFIRI) with erlotinib (OSI-774): early termination due to increased toxicities.

Messersmith WA, Laheru DA, Senzer NN, Donehower RC, Grouleff P, Rogers T, Kelley SK, Ramies DA, Lum BL, Hidalgo M.

Clin Cancer Res. 2004 Oct 1;10(19):6522-7.

40.

Temozolomide in patients with advanced cancer: phase I and pharmacokinetic study.

Rudek MA, Donehower RC, Statkevich P, Batra VK, Cutler DL, Baker SD.

Pharmacotherapy. 2004 Jan;24(1):16-25.

PMID:
14740784
41.

Phase I study of docosahexaenoic acid-paclitaxel: a taxane-fatty acid conjugate with a unique pharmacology and toxicity profile.

Wolff AC, Donehower RC, Carducci MK, Carducci MA, Brahmer JR, Zabelina Y, Bradley MO, Anthony FH, Swindell CS, Witman PA, Webb NL, Baker SD.

Clin Cancer Res. 2003 Sep 1;9(10 Pt 1):3589-97.

42.

Phase II study of flavopiridol in patients with advanced colorectal cancer.

Aklilu M, Kindler HL, Donehower RC, Mani S, Vokes EE.

Ann Oncol. 2003 Aug;14(8):1270-3.

PMID:
12881391
43.

A phase I and pharmacologic study of pyrazoloacridine and cisplatin in patients with advanced cancer.

Dees EC, Rowinsky EK, Noe DA, O'Reilly S, Adjei AA, Elza-Brown K, Donehower RC.

Invest New Drugs. 2003 Feb;21(1):75-84.

PMID:
12795532
44.

A phase I pharmacokinetic and pharmacodynamic study of the DNA methyltransferase 1 inhibitor MG98 administered twice weekly.

Stewart DJ, Donehower RC, Eisenhauer EA, Wainman N, Shah AK, Bonfils C, MacLeod AR, Besterman JM, Reid GK.

Ann Oncol. 2003 May;14(5):766-74.

PMID:
12702532
45.

Is HIF-1 alpha a valid therapeutic target?

Pili R, Donehower RC.

J Natl Cancer Inst. 2003 Apr 2;95(7):498-9. No abstract available.

PMID:
12671009
46.

Disposition of docosahexaenoic acid-paclitaxel, a novel taxane, in blood: in vitro and clinical pharmacokinetic studies.

Sparreboom A, Wolff AC, Verweij J, Zabelina Y, van Zomeren DM, McIntire GL, Swindell CS, Donehower RC, Baker SD.

Clin Cancer Res. 2003 Jan;9(1):151-9.

47.

Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001.

Baker SD, Verweij J, Rowinsky EK, Donehower RC, Schellens JH, Grochow LB, Sparreboom A.

J Natl Cancer Inst. 2002 Dec 18;94(24):1883-8.

PMID:
12488482
48.

Impact of prolonged infusions of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia.

Gore SD, Weng LJ, Figg WD, Zhai S, Donehower RC, Dover G, Grever MR, Griffin C, Grochow LB, Hawkins A, Burks K, Zabelena Y, Miller CB.

Clin Cancer Res. 2002 Apr;8(4):963-70.

49.

Metabolism and urinary excretion of a new quinoline anticancer drug, TAS-103, in humans.

Azuma R, Saeki M, Yamamoto Y, Hagiwara Y, Grochow LB, Donehower RC.

Xenobiotica. 2002 Jan;32(1):63-72.

PMID:
11820510
50.

Evolving therapies: farnesyltransferase inhibitors.

Purcell WT, Donehower RC.

Curr Oncol Rep. 2002 Jan;4(1):29-36. Review.

PMID:
11734111

Supplemental Content

Loading ...
Support Center